The first patients to receive Intellia's CRISPR-based therapy for hereditary angioedema saw their swelling attacks virtually ...

When palliative care is delivered via telehealth, there are a number of advantages. They can be at home, in their pajamas, ...

AstraZeneca is having another big ASCO, but the art of comfort care for cancer patients also got a plenary session.

At ASCO, Astra Zeneca reported that its drug Enhertu stalled the growth of tumors by more than a year in women with the most ...

The resurrection of a GSK blood cancer drug — which the company withdrew from the U.S. market not even two years ago — is ...

AstraZeneca reports at ASCO that its drug Tagrisso slowed down lung cancer progression for a median of several years in stage ...

Recap: Today's top stories from ASCO 2024 include updates on safety data about a myelofibrosis candidate, and record ...

The Biden administration has significantly opened the door to drug treatment strategies that help reduce substance use, even ...

At an ASCO 2024 event, Richard Pazdur, the FDA's top oncologist, said the agency wants to see companies conducting studies ...

At a STAT event, oncology leaders spoke of advances that are turning old ideas like antibody-drug conjugates into broadly ...

One data point makes new results on Pfizer's cancer drug Lorbrena quite eye-catching: It reduced disease progression by 81%.

Corbus, reporting on early trials of its antibody-drug conjugate, says it "seems to be clinically effective in bladder cancer ...